Newsbenzinga
Edwards Lifesciences Affirms FY2026 Adj EPS Guidance of $2.95-$3.05 vs $3.01 Est; Raises FY2026 Sales Guidance from $6.500B-$6.900B to $6.600B-$6.900B vs $6.745B Est
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…